Hizuru Amano1, Hiroo Uchida2, Yujiro Tanaka3, Takahisa Tainaka3, Makiko Mori4, Eiji Oguma5, Hiroshi Kishimoto6, Hiroshi Kawashima7, Yuki Arakawa4, Ryoji Hanada4, Katsuyoshi Koh4. 1. Department of Pediatric Surgery, Saitama Children's Medical Center, Saitama 330-8777, Japan; Department of Pediatric Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, 113-8655, Japan. 2. Department of Pediatric Surgery, Nagoya University Graduate School of Medicine, Aichi 466-8550, Japan. Electronic address: hiro2013@med.nagoya-u.ac.jp. 3. Department of Pediatric Surgery, Nagoya University Graduate School of Medicine, Aichi 466-8550, Japan. 4. Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama 330-8777, Japan. 5. Department of Radiology, Saitama Children's Medical Center, Saitama 330-8777, Japan. 6. Department of Pathology, Saitama Children's Medical Center, Saitama 330-8777, Japan. 7. Department of Pediatric Surgery, Saitama Children's Medical Center, Saitama 330-8777, Japan.
Abstract
BACKGROUND/ PURPOSE: The prognosis of patients with intermediate-risk neuroblastoma is favorable; therefore, a reduction therapy is desired. However, the long-term prognosis of those with residual tumor is unclear. The aim of this study was to clarify the necessity of residual tumor resection. METHODS: We retrospectively reviewed the records of patients diagnosed with intermediate-risk neuroblastoma who either were treated by chemotherapy only (nonresection group; n=16), or received postchemotherapy tumor resection (resection group; n=9). RESULTS: In the nonresection group, tumor size decreased in 14 patients; 5 had no detectable local tumor at the end of the follow-up period. Tumor size increased in 2 patients 1.5-2.5years postchemotherapy. Both patients received additional treatment and survived. All patients survived during the median follow-up time of 127months. In the resection group, 5 patients received complete resections and 4 patients received nearly complete resections. All patients survived during the median follow-up time of 84months. In 8 out of 9 resected tumors, regression or maturation was pathologically induced by chemotherapy-only treatment. CONCLUSION: Patients with intermediate-risk neuroblastoma with or without postchemotherapy residual tumor resection had an excellent long-term outcome. The tumor pathology with intermediate-risk neuroblastoma might be susceptible to change to regression or maturation by chemotherapy. LEVEL OF EVIDENCE: IV.
BACKGROUND/ PURPOSE: The prognosis of patients with intermediate-risk neuroblastoma is favorable; therefore, a reduction therapy is desired. However, the long-term prognosis of those with residual tumor is unclear. The aim of this study was to clarify the necessity of residual tumor resection. METHODS: We retrospectively reviewed the records of patients diagnosed with intermediate-risk neuroblastoma who either were treated by chemotherapy only (nonresection group; n=16), or received postchemotherapy tumor resection (resection group; n=9). RESULTS: In the nonresection group, tumor size decreased in 14 patients; 5 had no detectable local tumor at the end of the follow-up period. Tumor size increased in 2 patients 1.5-2.5years postchemotherapy. Both patients received additional treatment and survived. All patients survived during the median follow-up time of 127months. In the resection group, 5 patients received complete resections and 4 patients received nearly complete resections. All patients survived during the median follow-up time of 84months. In 8 out of 9 resected tumors, regression or maturation was pathologically induced by chemotherapy-only treatment. CONCLUSION:Patients with intermediate-risk neuroblastoma with or without postchemotherapy residual tumor resection had an excellent long-term outcome. The tumor pathology with intermediate-risk neuroblastoma might be susceptible to change to regression or maturation by chemotherapy. LEVEL OF EVIDENCE: IV.
Authors: Simone de Campos Vieira Abib; Chan Hon Chui; Sharon Cox; Abdelhafeez H Abdelhafeez; Israel Fernandez-Pineda; Ahmed Elgendy; Jonathan Karpelowsky; Pablo Lobos; Marc Wijnen; Jörg Fuchs; Andrea Hayes; Justin T Gerstle Journal: Ecancermedicalscience Date: 2022-02-17